Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
TSBX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-7.56
vs 0.52
Q3.23
N/A
-1.00
vs -0.73
Q4.23
N/A
-0.73
vs -0.62
Q1.24
N/A
-0.85
vs 0
Q2.24
N/A
-0.92
vs -7.56
Q3.24
N/A
-0.74
vs -1.00
Q4.24
N/A
-0.56
vs -0.73
Q1.25
N/A
-0.51
vs -0.85
Q2.25
N/A
-0.16
vs -0.92
Q3.25
N/A
-0.14
vs -0.74
Sales Growth
YoY
Current
Estimates
Q1.23
+80%
19.3M vs 10.7M
Q2.23
-100%
NA vs 41.9M
Q3.23
-100%
NA vs 10.2M
Q4.23
-100%
NA vs 10.4M
Q1.24
-100%
NA vs 19.3M
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
NA vs NA
Q1.25
NA
NA vs NA
Return on Equity
QoQ
Q2.23
+18%
0.18
vs -0.00
Q3.23
-15%
-0.15
vs 0.18
Q4.23
-17%
-0.17
vs -0.15
Q1.24
-25%
-0.25
vs -0.17
Q2.24
-36%
-0.36
vs -0.25
Q3.24
-39%
-0.39
vs -0.36
Q4.24
-41%
-0.41
vs -0.39
Q1.25
-59%
-0.59
vs -0.41
Institutionnal Ownership
QoQ
Q3.23
35
35
vs NA
NA
Q4.23
36
36
vs 35
3%
Q1.24
40
40
vs 36
11%
Q2.24
44
44
vs 40
10%
Q3.24
24
24
vs 44
-45%
Q4.24
28
28
vs 24
17%
Q1.25
23
23
vs 28
-18%
investorplace.com
8 hours ago
zacks.com
13 hours ago
globenewswire.com
18 hours ago
globenewswire.com
21 hours ago
Quote Panel
Key Metrics
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.03 ( 7.61%)
After-hours 0.34$
-0.04 (-9.97%)
Relative Strenght
10
Volume Buzz
-69%
Earning Acce
Yes
Dist 52w H.
88%Relative Strength
TSBX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
0%2026-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Bank of America Securities
downgradePrevious: Not converted
2024-10-14
Now: Reduce
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How TSBX compares to sector?
TSBX
0x